drugset / Trial / NCT00336518

Continuing Treatment With Pegasys and Copegus

NCT00336518

RandomizedParallel-groupOpen-labelTreatment

Summary

Primary objective is to measure sustained viral response given to continuation or prolongation of combined Pegasys\&Copegus treatment Secondary objective is to measure histological response given to continuation or prolongation of combined Pegasys\&Copegus treatment measured by non-invasive methods

Timeline

Start
2006-06
Primary completion
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon alfa-2a Protein / enzyme biologic 180 ug
Subject Ribavirin Small molecule 1000 mg
Subject Ribavirin Small molecule 1200 mg